AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AstraZeneca and GSK, along with Aurora Cannabis Inc., are involved in hiring Faris El Refaie for global commercial leadership, gaining experience in the pharmaceutical sector.Sub-event
- Pharmaceutical companies, including AbbVie and GSK, funded studies comparing drug spending, with Michael Johnson discussing Australia vs. New Zealand spending.Sub-event
Major drug companies (AbbVie, AstraZeneca, GSK) are facing challenges in the drug class and are involved in licensing deals with Chinese biotechs.1 source
Keep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
AstraZeneca
British-Swedish pharmaceutical company
-
GSK
British multinational pharmaceutical and biotechnology company
Related events
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- GSK and Amgen are major biopharma players.
- Alnylam Pharmaceuticals announced new partnerships with AstraZeneca for drug development and with Ionis Pharmaceuticals for clinical trials.
- GSK and Novartis are identified as major pharmaceutical companies.
- Chinese pharmaceutical companies are investing heavily in novel technologies while AstraZeneca confirms its Cambridge headquarters and CEO.